Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.64 |
| ▸ | RELA | Q04206 | 3/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2750303 | 0.95 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL2750555 | 0.91 | ALDH2 (0.64) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10119567 | 0.85 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16473743 | 0.84 | ACHE (0.49) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7565407 | 0.82 | MEN1 (0.64) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL13492287 | 0.79 | NPC1 (0.64) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16460017 | 0.79 | ALDH2 (0.71) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| Biochanin SCHEMBL61258 | 0.79 | RAB9A (1.00) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| Biochanin SCHEMBL29410271 | 0.79 | RAB9A (1.00) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7588164 | 0.78 | MEN1 (0.72) | MEN1KMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623910-B2 | Isoflavones for treating mucopolysaccharidoses | INSTYTUT FARMACEUTYCZNY (PL) | 2014-01-07 | — | — | US | claimed |
| US-8178609-B2 | Isoflavones for treating mucopolysaccharidoses | INSTYTUT FARMACEUTYCZNY (PL) | 2012-05-15 | — | — | US | claimed |
| US-20140107051-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | INSTYTUT FARMACEUTYCZNY (PL) | 2014-04-17 | — | — | US | disclosed |
| US-8623910-B2 | Isoflavones for treating mucopolysaccharidoses | INSTYTUT FARMACEUTYCZNY (PL) | 2014-01-07 | — | — | US | disclosed |
| US-8623910-B2 | Isoflavones for treating mucopolysaccharidoses | INSTYTUT FARMACEUTYCZNY (PL) | 2014-01-07 | — | — | US | disclosed |
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2013-01-31 | — | — | US | disclosed |
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2013-01-31 | — | — | US | disclosed |
| US-20120190642-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | INSTYTUT FARMACEUTYCZNY (PL) | 2012-07-26 | — | — | US | disclosed |
| US-8178609-B2 | Isoflavones for treating mucopolysaccharidoses | INSTYTUT FARMACEUTYCZNY (PL) | 2012-05-15 | — | — | US | disclosed |
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2012-04-05 | — | — | US | disclosed |
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2012-04-05 | — | — | US | disclosed |
| US-8071575-B2 | Methods and compounds for the targeted delivery of agents to bone for interaction therewith | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071575-B2 | Methods and compounds for the targeted delivery of agents to bone for interaction therewith | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090118164-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2009-05-07 | — | — | US | disclosed |
| US-20090118164-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2009-05-07 | — | — | US | disclosed |
| US-20090062380-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | INSTYTUT FARMACEUTYCZNY (PL) | 2009-03-05 | — | — | US | disclosed |
| WO-2008103951-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | MEN1 1822/4885KMT2A 3983/4885SMN1; SMN2 3404/4885 |
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | MEN1 1822/4885KMT2A 3983/4885SMN1; SMN2 3404/4885 |
| US-20140107051-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | GAA, MAN2B1, IDUA | MEN1 1704/4885KMT2A 1912/4885SMN1; SMN2 22/4885 |
| US-20090062380-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | GAA, IDUA, MAN2B1 | MEN1 3227/4885KMT2A 1810/4885SMN1; SMN2 437/4885 |
| US-20120190642-A1 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES | GAA, MAN2B1, IDUA | MEN1 1721/4885KMT2A 1734/4885SMN1; SMN2 21/4885 |
| US-20090118164-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | MEN1 1822/4885KMT2A 3983/4885SMN1; SMN2 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.